Skip to content
Screener

PTC Therapeutics PTCT Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$211.0MMiss by $70.4M
EPS$0.20Beat by $1.39
Revenue estimate$281.5M
EPS estimate-$1.19

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$303.9M
EPS estimate$0.29

Financials

Q3 2025

Income statement

See full
Revenue$211.0M+7.2%
Operating income$3.0M+106%
Net income$15.9M+115%
EPS (diluted)$0.20+114%

Balance sheet

See full
Cash & equivalents$672.6M+27.9%
Total debt$410.1M+1.8%
Total equity-$155.8M+85.2%
Total assets$2.6B+43.5%

Cash flow

See full
CapEx$3.4M+560%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$4.88B+71.3%
Enterprise value$4.61B+69.4%
P/E6.5×—
P/S2.7×-0.4×

Profitability

See full
Operating margin43.6%+34.5pp
Net margin42.3%+27.4pp

Returns & leverage

See full
Current ratio2.3×+0.2×

Segments

By product

See full
Translarna$50.7M—
Emflaza$35.2M—
Sephience$19.6M—
Other Products$9.8M—

By segment

See full
Life Science$211.0M+7.2%

FAQ

When did PTC Therapeutics report Q3 2025 earnings?
PTC Therapeutics (PTCT) reported Q3 2025 earnings on November 4, 2025 after market close.
What were PTC Therapeutics's Q3 2025 revenue and EPS?
PTC Therapeutics reported revenue of $211.0M and eps of $0.20 for Q3 2025.
Did PTC Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $281.5M by $70.4M. EPS beat the consensus estimate of $-1.19 by $1.39.
How did PTC Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.2% from $196.8M a year earlier.
Where can I find PTC Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001070081-25-000026) and the 10-Q periodic report (0001070081-25-000028) directly on SEC EDGAR. The filing index links above go to sec.gov.